Discovery
of a new drug is time-consuming, laborious, and expensive.
Herein, a novel integrative strategy for discovering potential new
lead compounds has been developed, which was based on the characteristics
of mass spectrometry (MS). MS was used to predict the potential forced
degradation products (DPs) and metabolites of drugs by electrospray
ionization and collision-induced dissociation (CID). Special rearrangement
ions representing unique predicted DPs and metabolites were identified.
The consistency between the predicted and the measured results was
proven by in vitro metabolism and forced degradation
of a commercial drug, respectively. From this, new chemical scaffold
rearrangement ions named (aza)-biphenylenes, as potent anticancer
agents, were discovered. As a representative aza-biphenylene analogue,
2-azabiphenylene was proven in vitro to induce apoptosis
and inhibit the growth of various human cancer cells in a dose-dependent
manner. Surprisingly, 2-azabiphenylene exhibited the best comparable
bioactivity with the positive control sorafenib, but showed significantly
lower in vitro cytotoxicity than sorafenib (at least
a 5-fold decrease in cytotoxicity) because it could be targeted to
the tumor microenvironment at low pH. A biradical mechanism accompanied
by a mitochondrion-dependent oxidative stress mechanism was proposed
to explore its anticancer mechanism. The highly reactive intermediate
aza-biphenylenediyl worked as an active pharmaceutical ingredient
and induced apoptosis of cancer cells. This provided the basis for
the potential applications of CID-induced special rearrangement ions
in developing new lead compounds.